Can measuring DNA transcription infidelity enable a more personalised approach to treating cancer?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Can measuring DNA transcription infidelity enable a more personalised approach to treating cancer?
Released on: March 24, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Bernard Bihain, CEO to Genclis SAS, reveals how their diagnostic approach could help clinicians predict the severity of cancers, and devise more optimised treatment plans.
  • Summary
  • Transcript
  • Participants
  • Company
Bernard Bihain, CEO to Genclis SAS, reveals how their diagnostic approach could help clinicians predict the severity of cancers, and devise more optimised treatment plans.
Bernard Bihain, CEO to Genclis SAS, reveals how their diagnostic approach could help clinicians predict the severity of cancers, and devise more optimised treatment plans.
Bernard created Glenclis in 2004. After a Doctorate in Medicine from the University of Brussels, Bernard began an internship in surgery he left to devote himself exclusively to research in the context of a post-doctorate at Columbia University, New York, USA. He was appointed Assistant Professor of Physiology at the University of Louisiana, New Orleans, United States. Bernard is received at Inserm research director contest and became Professor and Chair of the Biochemistry Department of the University of Rennes which is created Inserm Unit 391, he leads. He then became head of the Department of Functional Genomics Genset, genomics listed company and sold to Merck-Serono. He then became CSO Valigen he left to devote himself to the creation of Genclis. He actively contributed to the emergence of genomic technologies, his surgeon pragmatism is the driving translational activities Genclis. Bernard is the author of over 50 publications in refereed journals. His work is cited in over 5,000 scientific articles.
Genclis